Aldosterone-renin ratio and plasma renin activity as biomarkers for treatment response in resistant hypertension.

Hypertens ResAug 19, 2026 (epub)
Clinical ResearchCardiologyEndocrinologyOpen access

Kyeong-Hyeon Chun, Chan Joo Lee, Dong-Ho Shin et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of a randomized controlled trial assessed the relationship between baseline aldosterone-renin ratio (ARR) and plasma renin activity (PRA) with treatment response in 114 patients with resistant hypertension. The study found that spironolactone was more effective in reducing home systolic blood pressure (SBP) in patients with higher ARR (-18.8 ± 11.6 mmHg) compared to those with lower ARR (-9.8 ± 8.4 mmHg).

Key findings

  • Spironolactone reduced home SBP more in patients with higher ARR (-18.8 ± 11.6 mmHg) than in those with lower ARR (-9.8 ± 8.4 mmHg).
  • Lower PRA was associated with a greater reduction in home SBP with spironolactone (-19.1 ± 11.8 mmHg vs -10.1 ± 8.4 mmHg).
  • No significant difference in SBP reduction was observed with amiloride based on ARR or PRA.

Why it matters

Understanding the influence of renin-aldosterone status on treatment response can guide clinicians in selecting the most effective antihypertensive therapy for patients with resistant hypertension, potentially improving patient outcomes.

Source

PubMed · PMID 42618626Free full text on PubMed Central

Published in Hypertens Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.